Sorafenib therapy in advanced hepatocellular carcinoma: The SHARP trial

Expert Review of Anticancer Therapy

Volumn 9, Issue 6, 2009, Pages 739-745

  Rimassa, Lorenza ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Advanced disease; Hepatocellular carcinoma; Safety; SHARP trial; Sorafenib; Targeted therapies; Unresectable disease

Indexed keywords

DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; HAND FOOT SYNDROME; HUMAN; HYPOPHOSPHATEMIA; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MONOTHERAPY; OVERALL SURVIVAL; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR CELL; VOICE; WEIGHT REDUCTION; AGED; DISEASE COURSE; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; LIVER FUNCTION TEST; LIVER TUMOR; MORTALITY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 68849110551     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.41     Document Type: Article

References (40)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
2. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 23(11), 1535-1547 (2006).
3. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27(1), 55-76 (2007).
4. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41(5), 864-880 (2004).
5. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48(4), 1312-1327 (2008).
6. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br. J. Cancer. 100(1), 19-23 (2009).
7. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 100(1), 1-8 (2009).
8. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
9. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59(5), 561-574 (2007).
10. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
11. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23(5), 965-972 (2005).
12. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).
13. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
14. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia - Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
15. Abou-Alfa G, Johnson P, Knox J et al. Final results from a Phase II (Phil), randomized, double-blind, study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). Presented at: 2008 Gastrointestinal Cancer Symposium. FL, USA, 25-27 January 2008 (Abstract 128).
16. Keating GM, Santoro A. Sorafenib. A review of its use in hepatocellular carcinoma. Drugs 69(2), 223-240 (2009).
17. Llovet JM, Peña C, Shan M, Jeffers M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from the randomized Phase III SHARP trial. Presented at: The 59th Annual Meeting of the American Association for the Study of Liver Diseases. CA, USA, 31 October-4 November 2008 (Abstract 149).
18. Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J. Clin. Oncol. 26(36), 5845-5848 (2008).
19. Bolondi L, Caspary W, Bennouna J et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Presented at: 2008 Gastrointestinal Cancer Symposium. Orlando, FL, USA, 25-27 January 2008 (Abstract 129).
20. Guan Z, Kang YK, Chen Z et al. Sorafenib is effective in hepatitis-B positive patients with hepatocellular carcinoma (HCC): subgroup analysis of a randomized, double-blind, Phase III trial performed in the Asia - Pacific region. Presented at: 33rd ESMO Congress. Stockholm, Sweden, 12-16 September 2008 (Abstract 512PD).
21. Galle P, Blanc J, Van Laethem JL et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008 (Abstract 994).
22. Raoul J, Santoro A, Beaugrand M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: a subanalysis from the SHARP trial. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. IL, USA, 30 May-3 Jun 2008 (Abstract 4587).
23. Kang YK, Guan Z, Chen Z et al. Sorafenib is effective in patients from the Asia - Pacific region with hepatocellular carcinoma (HCC): subgroup analysis of effect of macroscopic vascular invasion, extrahepatic spread, and ECOG performance status on outcome. Presented at: The 59th Annual Meeting of the American Association for the Study of Liver Diseases. CA, USA, 31 October-4 November 2008 (Abstract 1505).
24. Greten T, Scherübl J, Scheulen M et al. Baseline transaminase levels and efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): a subgroup analysis of SHARP. Presented at: 2008 Gastrointestinal Cancer Symposium. FL, USA, 25-27 January 2008 (Abstract 197).
25. Craxi A, Porta C, Sangiovanni A et al. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: a subanalysis from the SHARP trial. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 15591).
26. Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4518).
27. Weinmann A, Schrabback P, Schulze-Bergkamen H et al. α-feto-protein levels during treatment with sorafenib in patients with advanced hepatocellular carcinoma. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008 (Abstract 417).
28. 18F-fluorodeoxyglucose - positron emission tomography. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. IL, USA, 30 May-3 June 2008 (Abstract 15600).
29. Galle PR. Sorafenib in advanced hepatocellular carcinoma - we have won a battle not the war. J. Hepatol. 49(5), 871-873 (2008).
30. Roberts LR. Sorafenib in liver cancer: just the beginning? N. Engl. J. Med. 359(4), 420-422 (2008).
31. Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14, 70-76 (2009).
32. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 9(2), 117-123 (2008).
33. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23(27), 6657-6663 (2005).
34. Thomas MB, Morris JS, Chadha R et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J. Clin. Oncol. 27(6), 843-850 (2009).
35. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effect of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 26(18), 2992-2998 (2008).
36. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(12), 1898-1903 (2006).
37. Faivre SJ, Raymond E, Douillard J et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology. IL, USA, 2-5 June 2007 (Abstract 3546).
38. Zhu AX, Sahani DV, di Tomaso E et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary Phase II study. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 4521).
39. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and end-points of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100(10), 698-711 (2008).
40. Finn RS, Kang Y, Park J, Harris R, Donica M, Walters I. Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. Presented at: 2009 Gastrointestinal Cancer Symposium. CA, USA, 15-17 January 2009 (Abstract 200).